News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Savient Pharmaceuticals, Inc. (SVNT) Submits New Drug Application For Soltamox To The U.S. FDA



10/19/2005 5:11:56 PM

EAST BRUNSWICK, N.J.--(BUSINESS WIRE)--Jan. 6, 2005--Savient Pharmaceuticals, Inc. (NASDAQ: SVNT), an emerging specialty pharmaceutical company engaged in developing, manufacturing and marketing pharmaceutical products that address unmet medical needs is pleased to announce the submission of a New Drug Application ("NDA") with the U.S. Food and Drug Administration ("FDA") of Soltamox(R) (tamoxifen oral liquid solution) for the treatment of hormonally sensitive breast cancer. Soltamox is the product of Savient's wholly-owned subsidiary, Rosemont Pharmaceuticals Ltd. located in Leeds, U.K.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES